National Pension Service Buys 63,554 Shares of Medtronic PLC $MDT

National Pension Service boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,954,142 shares of the medical technology company’s stock after acquiring an additional 63,554 shares during the quarter. National Pension Service’s holdings in Medtronic were worth $281,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Corundum Trust Company INC bought a new position in shares of Medtronic during the third quarter valued at about $27,000. Valley Wealth Managers Inc. purchased a new position in Medtronic during the 3rd quarter valued at about $29,000. Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in Medtronic in the 3rd quarter worth approximately $34,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MDT. Robert W. Baird set a $103.00 target price on Medtronic in a report on Tuesday, December 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday. They issued an “overweight” rating and a $114.00 price objective for the company. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Trading Up 1.9%

NYSE:MDT opened at $102.96 on Friday. The firm has a market capitalization of $131.99 billion, a P/E ratio of 27.75, a PEG ratio of 2.66 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The company’s 50-day simple moving average is $99.60 and its 200 day simple moving average is $95.64.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the business earned $1.26 earnings per share. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).